Pharmaceutical giant Gilead is teaming up with Silicon Valley startup Insitro to develop better drugs for a quietly emerging disease called NASH. Short for non-alcoholic steatohepatitis, NASH can lead to liver failure and is estimated to affect some 16 million Americans. Insitro is led by the former chief computing officer of Google life-extension spinoff Calico. It has backing from top-notch tech investors like Jeff Bezos and life science firms like Verily. The three-year deal could be worth as much as $250 million for Insitro. Visit BusinessInsider.com for more stories.